This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Alert me on articles by topic  Social Bookmarking   What's this?

Neal Ready, MD; Martin A. Weinstock, MD, PhD

Arch Dermatol. 2003;139:1635-1637.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials
Lens MB, Dawes M
J Clin Oncol. 2002;20:1818-1825

Question: Does adjuvant interferon alfa improve survival after resection of stage I, II, or III malignant melanoma?

Data Sources: Electronic searches of MEDLINE (1966-March 2001), EMBASE (1974-March 2001), and the Controlled Trials Register from the Cochrane Library (issue 4, 2000) using medical subject headings (MeSH) "melanoma" and "interferon alpha." Also, review articles, textbooks, conference proceedings, and discussions with experts in the field were used to identify other published or unpublished data.

Study Selection: Trials were included if they were randomized and controlled and evaluated interferon alfa as adjuvant monotherapy in patients with clinically diagnosed stage I, II, or III cutaneous melanoma.

Data Extraction: The following variables were extracted from each study: randomization process, strategy for concealment of allocation, number . . . [Full Text of this Article]

Comment

Brown University School of Medicine and Veterans Affairs Medical Center, Providence, RI

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?